

NCI Budget Update

Patrick McGarey, J.D., MBA
Assoc. Director for Finance & Legislation

NCAB Subcommittee on Planning & Budget
June 13, 2022

patrick.mcgarey2
@nih.gov

Agenda

FY 2022 NCI Budget & R01 Payline

- Budget Impact of Type 5 (non-competing) R01s
- Outlook for 15-by-25 (15th percentile by FY 2025)


FY 2023 NCI Budget vs. FY 2022

President Biden's Supercharged Moonshot

NCI Appropriations

FY 2015 – 2022 (in millions)

21st Century Cures Act - orange
 Childhood Cancer Initiative - green



Also, ARPA-H: \$1B
 (available FY 2022 - 24)

NCI R01 & Non-Competing Grant Funding Policies

Competing Grants		Noncompeting Grants
Type	Payline	
R01 Grants for Established and New Investigators	11th Percentile	Will be funded at 98% of the committed level.
R01 Grants for Early-Stage Investigators (ESIs)	16th Percentile	Exempt from the 2% reduction: <ul style="list-style-type: none"> • Most ESI awards • Training awards • R00, R03, R50 • SBIR/STTR awards • P30 Cancer Center awards
R21 Exploratory Grants	9th Percentile	

For details, see [NCI FY 2022 Grant Funding Policies](#)

Agenda (cont'd)

FY 2022 NCI Budget & R01 Payline

- **Budget Impact of Type 5 (non-competing) R01s**
- Outlook for 15-by-25 (15th percentile by FY 2025)

FY 2023 NCI Budget vs. FY 2022

President Biden's Supercharged Moonshot

Exhibit on Payline Costs, [April 1, 2022 NCI Bottom Line Blog](#)

FY 2020	FY 2021	FY 2022	Future Fiscal Years
Increase R01 payline from the 8th to the 10th percentile	Increase R01 payline to 11th percentile	Maintain R01 payline at 11th percentile	
\$75M increase to pay competing grants	<i>Costs continue for 4 FYs</i>	<i>Costs continue for 3 FYs</i>	<i>Costs continue for 2 FYs</i>
	\$27M increase to pay competing grants	<i>Costs continue for 4 FYs</i>	<i>Costs continue for 3 FYs</i>
		\$39M increase to pay competing grants	<i>Costs continue for 4 FYs</i>

R01 Competing Grant Commitments FY 2020 – 2022

NCI Competing Grants, Year by Year		
FY 2020	FY 2021	FY 2022
<u>Raise</u> R01 Payline from 8th to 10th Percentile	<u>Raise</u> R01 Payline to 11th Percentile	<u>Maintain</u> R01 Payline at 11th Percentile

NCI FY 2020 R01 Payline Commitment

FY 2020

**Raise R01 Payline from
8th to 10th Percentile**

**+\$75M to pay
competing grants**

5-Year Consequences of 2020 R01 Payline Commitment

FY 2020	FY 2021	FY 2022	FY 2023	FY 2024
Raise R01 Payline from 8th to 10th Percentile				
+\$75M to pay competing grants	<i>+\$75M costs continue for 4 fiscal years</i>	<i>+\$75M costs continue for 3 fiscal years</i>	<i>\$75M costs continue for 2 fiscal years</i>	<i><u>Final fiscal year</u> for +\$75M costs</i>

NCI FY 2021 R01 Payline Commitment

FY 2021


**Raise R01 Payline
to 11th Percentile**

**+\$27M to pay
competing grants**

5-Year Consequences of 2021 R01 Payline Commitment

FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
<u>Raise R01 Payline to 11th Percentile</u>				
+\$27M to pay competing grants	<i>+\$27M costs continue for 4 fiscal years</i>	<i>+\$27M costs continue for 3 fiscal years</i>	<i>+\$27M costs continue for 2 fiscal years</i>	<u>Final fiscal year for +\$27M costs</u>

NCI FY 2022 R01 Payline Commitment



5-Year Consequences of 2022 R01 Payline Commitment

FY 2022	FY 2023	FY 2024	FY 2025	FY 2025
<u>Maintain</u> R01 Payline at 11th Percentile				
		-		
			-	
+\$39M to pay competing grants	<i>+\$39M costs continue for 4 fiscal years</i>	<i>+\$39M costs continue for 3 fiscal years</i>	<i>+\$39M costs continue for 2 fiscal years</i>	<i><u>Final fiscal year</u> for +\$39M costs</i>

FY 2020 – 2022 R01 Competing & Non-Competing Commitments

Financial Consequences of Increasing Funds for Competing Grants, Year by Year						
FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2025
<u>Raise R01 Payline from 8th to 10th Percentile</u>	<u>Raise R01 Payline to 11th Percentile</u>	<u>Maintain R01 Payline at 11th Percentile</u>	Payline T.B.D.	Payline T.B.D.	Payline T.B.D.	Payline T.B.D.
+\$75M to pay competing grants →	<i>+\$75M costs continue for 4 fiscal years</i> →	<i>+\$75M costs continue for 3 fiscal years</i> →	<i>\$75M costs continue for 2 fiscal years</i> →	<i>Final fiscal year for +\$75M costs</i>		
	+\$27M to pay competing grants →	<i>+\$27M costs continue for 4 fiscal years</i> →	<i>+\$27M costs continue for 3 fiscal years</i> →	<i>+\$27M costs continue for 2 fiscal years</i> →	<i>Final fiscal year for +\$27M costs</i>	
		+\$39M to pay competing grants →	<i>+\$39M costs continue for 4 fiscal years</i> →	<i>+\$39M costs continue for 3 fiscal years</i> →	<i>+\$39M costs continue for 2 fiscal years</i> →	<i>Final fiscal year for +\$39M costs</i>

Other Grant-Related Factors to Consider

Commitment to Grow Grant Volume –

- NCI issues R01s for 5 years.
- In year 6, NCI makes new awards with funds from old, expiring R01s.
- But, each year, NCI strives to issue more awards
- Old award dollars don't cover the cost of the larger volume of new R01s

Inflation –

- 5 years of inflation depletes the buying power of the old R01 dollars

ESI R01s to R37s –

- Most meritorious Early-Stage Investigator R01s can convert to 7-year R37s

Agenda (cont'd)

FY 2022 NCI Budget & R01 Payline

- Budget Impact of Type 5 (non-competing) R01s
- **Outlook for 15-by-25 (15th percentile by FY 2025)**

FY 2023 NCI Budget vs. FY 2022

President Biden's Supercharged Moonshot

NCI Annual Plan Affirms 15x25 Priority

FY 2023 NCI Annual Plan – *Key Messages*

NCI is committed to investigator-initiated research.

The FY 2023 budget proposal would enable NCI to increase R01 paylines to the 13th percentile, allowing NCI to fund a greater number of meritorious applications. Robust and sustained investments are needed to achieve the 15th percentile R01 payline by FY 2025.

Path to the 15th Percentile –

- **FY 2023 A.P.** – A.P. budget target aligns with NCI priority to fund the top 15th percentile of R01s by 2025
- **60% Growth** – Raising the FY 2023 R01 payline to the 13th percentile is a 60% increase compared to FY19.
- **R01 grants** – Among the most innovative and transformative ideas in cancer research.

Agenda (cont'd)

FY 2022 NCI Budget & R01 Payline

- Budget Impact of Type 5 (non-competing) R01s
- Outlook for 15-by-25 (15th percentile by FY 2025)

FY 2023 NCI Budget vs. FY 2022

President Biden's Supercharged Moonshot

FY 2022 vs. FY 2023 Budget, NCI & NIH

NIH FY 2022 enacted budget: +\$3.24B (+7.6%)*

- Includes \$1B for ARPA-H, transferred to NIH 4/15/22

NCI FY 2022 enacted budget: +\$353M (+5.4%)

- +\$150M targeted for NCI Competing & Continuing Grants

NIH FY 2023 proposed budget: +\$16.3B (+35.3%)**

- Includes \$5B for ARPA-H and \$12B for Pandemic Preparedness

NCI FY 2023 proposed budget: -\$199M (-2.9%)

Dr. Tabak addresses Qs on FY 2023 NIH Budget

THE NIH DIRECTOR

April 7, 2022

Insights on the Federal Budget Process and What it Means for NIH Research

“The administration built its FY 2023 budget proposal using the FY 2022 Continuing Resolution as the current year baseline because appropriations were significantly delayed this year.”

- FY22 appropriations arrived “too late to adjust the numbers in the President’s Budget” for FY23.
- Final FY22 Funding Bill 3/15/22
- Proposed FY23 Budget 3/28/22
- Result: NCI budget dropped \$199M (-2.9%)
- FY23 Budgets for NCI and 11 other NIH institutes are negative



Pause for Questions?

Agenda (cont'd)

FY 2022 NCI Budget & R01 Payline

- Budget Impact of Type 5 (non-competing) R01s
- Outlook for 15-by-25 (15th percentile by FY 2025)

FY 2023 NCI Budget vs. FY 2022

President Biden's Supercharged Moonshot

White House Commitment to New Cancer Moonshot



“I’m proud to announce our plan to supercharge the Cancer Moonshot as a central effort of the Biden-Harris administration... This is a presidential priority. I will do my part on funding and using my authority as president to speed breakthroughs. I challenge and encourage all of you to do your part.”

— *President Joe Biden (February 2, 2022)*

Goals of Biden Cancer Moonshot – Next Phase

- 1** Cut the cancer death rate in half within 25 years
- 2** Transform the meaning of cancer
- 3** Address cancer-associated inequities

New White House Cancer Mortality Goal

1990 215 deaths per 100,000

2019 146 deaths per 100,000

In 25 years...

73 deaths per 100,000



“The goal is to cut the cancer death rate in half in the next 25 years.”

— President Biden
Feb. 2, 2022

5/4/22 – NCI Spotlights Doubling Clinical Trial Accrual

CANCER MOONSHOT
PRESIDENT JOE BIDEN

NIH NATIONAL CANCER INSTITUTE

**CANCER CABINET COMMUNITY CONVERSATIONS:
DOUBLING CLINICAL TRIALS ACCRUAL**

Wednesday, May 4
12:00 p.m. – 12:45 p.m. ET

Hello, everyone. I am Dr. Doug Lowy.
YouTube | Facebook | Twitter



- Organized by Biden Cancer Cabinet – NCI Topic: *Doubling clinical trial accrual*
- Wide support voiced for doubling accrual among patients, scientists, advocates, and biomedical leaders
- Broad recognition that clinical trials are essential to advance discoveries from lab to patients



Questions?

Thank You